高剂量放疗对局部区域未控制的IV期乳腺癌乳腺肿瘤的影响:需要风险分层方法
本研究回顾性分析了133例接受乳腺姑息性放疗的局部区域未控制IV期乳腺癌患者,中位总剂量45 Gy(EQD2 53 Gy)。中位随访17.2个月,2年局部控制率和总生存率分别为49.4%和48.3%。无风险因素组2年局部控制和总生存分别为63.9%和72.8%,而2个风险因素组均为0%和6.8%。作者结论认为,对于乳腺外病灶稳定且既往系统治疗≤2线的患者,乳腺姑息性放疗显示良好的局部控制,并建议未来开展临床试验研究高于姑息剂量及早期干预的作用。
要点
- 中位随访17.2个月,2年局部控制率和总生存率分别为49.4%和48.3%。
- 无风险因素组2年局部控制和总生存分别为63.9%和72.8%,2个风险因素组分别为0%和6.8%。
- EQD2≥63 Gy的乳腺姑息性放疗在组1中显著改善局部控制,组2仅边缘获益(p=0.055),组3无改善(p=0.300)。
核心结论
- 乳腺姑息性放疗在乳腺外病灶稳定且既往系统治疗≤2线的患者中显示良好的局部控制结局。
- 作者认为需要未来临床试验研究高于姑息剂量及早期乳腺姑息性放疗干预在IV期患者中的作用。
研究设计与样本
- 回顾性分析133例接受乳腺姑息性放疗的局部区域未控制IV期乳腺癌患者。
- 中位总剂量45 Gy,等效2 Gy分次剂量(EQD2,α/β=3.5)为53 Gy。
- 采用Cox比例风险模型分析局部控制的预后因素。
主要发现
- 90.2%的患者为多转移性疾病(>5个病灶),48.9%有骨转移。
- 中位随访17.2个月,2年局部控制率和总生存率分别为49.4%和48.3%。
- 多因素分析显示,乳腺外病灶进展或混合反应以及既往治疗>2线为临床结局的不良因素。
- 组1(0个风险因素)2年局部控制率和总生存率分别为63.9%和72.8%,组3(2个风险因素)分别为0%和6.8%。
- EQD2≥63 Gy的乳腺姑息性放疗在组1中显示局部控制显著获益,组2仅边缘获益(p=0.055),组3无改善(p=0.300)。
临床怎么用
- 作者认为,对于乳腺外病灶稳定且既往系统治疗≤2线的患者,乳腺姑息性放疗可显示良好的局部控制结局。
- 作者建议未来开展临床试验研究高于姑息剂量及早期乳腺姑息性放疗干预在IV期患者中的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Patients with locoregionally uncontrolled breast tumors are frequently referred for breast palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following breast PRT to optimize PRT according to risk groups. METHODS: We reviewed 133 patients who underwent breast PRT. A median total dose of 45 Gy was prescribed with an equivalent dose in 2 Gy fractions (EQD2, α/β = 3.5) of 53 Gy. The Cox proportional hazards model was used to analyze the prognostic factors of local control (LC). RESULTS: Most (90.2%) had polymetastatic disease (> 5 lesions), and 48.9% had bone metastasis. With a median follow-up of 17.2 months, the 2-year LC and overall survival (OS) rates were 49.4%, and 48.3%, respectively. Multivariable analyses demonstrated progressive or mixed responses outside the breast and > 2 lines of previous therapy as adverse features for clinical outcomes. Group 1 (0 risk factors) showed favorable 2-year LC and OS of 63.9%, and 72.8%, respectively, whereas group 3 (2 risk factors) showed the worst outcomes of 0%, and 6.8%, respectively. Breast PRT with EQD2 ≥ 63 Gy showed a significant benefit in LC for group 1 and marginal benefit (p = 0.055) for group 2, but no improvement for group 3 (p = 0.300). CONCLUSION: Breast PRT showed favorable LC outcomes in patients with stable disease outside the breast and treated with ≤ 2 lines of systemic treatment. Our findings warrant future clinical trials investigating the role of higher than palliative dose and early intervention of PRT in stage IV patients.
引用
- Kim N, Kim H, Park W, et al. Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach. Radiat Oncol. 2023. PMID: 37821947. doi:10.1186/s13014-023-02357-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。